← Back to Search

Intrahepatic Cholangiocarcinoma, With Lymph node metastasis (Validation) for Bile Duct Cancer (LyMIC Trial)

N/A
Recruiting
Led By Ajay Goel, PhD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

LyMIC Trial Summary

Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.

Eligible Conditions
  • Bile Duct Cancer
  • Intrahepatic Cholangiocarcinoma
  • Cholangiocarcinoma
  • Liver Cancer

LyMIC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Sensitivity
Secondary outcome measures
Proportion of correct predictions (true positives and true negatives) among the total number of cases (i.e., accuracy)
Specificity

LyMIC Trial Design

4Treatment groups
Experimental Treatment
Group I: Intrahepatic Cholangiocarcinoma, Without Lymph node metastasis (Validation)Experimental Treatment1 Intervention
Patients with ICC who did not have lymph node metastases at the time of primary tumor treatment with D2 dissection, in the second cohort.
Group II: Intrahepatic Cholangiocarcinoma, Without Lymph node metastasis (Training)Experimental Treatment1 Intervention
Patients with ICC who did not have lymph node metastases at the time of primary tumor treatment with D2 dissection, in the first cohort.
Group III: Intrahepatic Cholangiocarcinoma, With Lymph node metastasis (Validation)Experimental Treatment1 Intervention
Patients with ICC who had lymph node metastases at the time of primary tumor treatment with D2 dissection, in the second cohort.
Group IV: Intrahepatic Cholangiocarcinoma, With Lymph node metastasis (Training)Experimental Treatment1 Intervention
Patients with ICC who had lymph node metastases at the time of primary tumor treatment with D2 dissection, in the first cohort.

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
568 Previous Clinical Trials
1,924,460 Total Patients Enrolled
Ajay Goel, PhDPrincipal InvestigatorCity of Hope Medical Center
9 Previous Clinical Trials
7,377 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Annals of SurgeryJournal
Intrahepatic Cholangiocarcinoma
Endo, Itaru, Mithat Gonen, Adam C. Yopp, Kimberly M. Dalal, Qin Zhou, David Klimstra, Michael D'Angelica, et al.. 2008. “Intrahepatic Cholangiocarcinoma”. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/sla.0b013e318176c4d3.
clinicaltrials.govStudy
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
2023. "Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06381648.
All > Anaheim > Paid Studies Ventura
~132 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top